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A B S T R A C T
1-Nitro-2-phenylethane is the ﬁrst organic NO2-containing molecule isolated from plants. It possesses
interesting hypotensive, bradycardic, and vasodilator properties, but the mode by which it induces
vasorelaxation is still unknown. The underlying mechanism involved in the vasodilator effect of 1-nitro-
2-phenylethane was investigated in rat aorta. The vasorelaxant effects of 1-nitro-2-phenylethane did not
depend on endothelial layer integrity, and the effects were refractory to L-NG-nitroarginine methyl ester
(L-NAME)-induced nitric oxide synthase inhibition. Vasorelaxation was similarly resistant to treatment
with indomethacin, cis-N-(2-phenylcyclopentyl)-azacyclotridec-1-en-2-amine hydrochloride (MDL-
12330A), and KT5720, indicating that neither prostaglandin release nor adenylyl cyclase activation is
involved. Conversely, methylene blue- and ODQ-induced guanylate cyclase inhibition reduced the
vasorelaxation induced by 1-nitro-2-phenylethane. The pharmacological blockade of K+ channels with
tetraethylammonium, glybenclamide, and 4-aminopyridine also blunted vasorelaxation induced by 1-
nitro-2-phenylethane. The effects of 1-nitro-2-phenylethane were reversed by 1H-[1,2,4]oxadia-
zolo[4,3-a]quinoxalin-1-one (ODQ) and comparable to the effects induced by sodium nitroprusside. In
silico analysis using an Ns H-NOX subunit of guanylate cyclase revealed a pocket on the macromolecule
surface where 1-nitro-2-phenylethane preferentially docked. In vitro, 1-nitro-2-phenylethane increased
cyclic guanosine 30,50-monophosphate (cGMP) levels in rat aortic rings, an effect also reversed by ODQ. In
conclusion, 1-nitro-2-phenylethane produces vasodilator effects by stimulating the soluble guanylate
cyclase-cGMP pathway.
 2012 Elsevier Inc. 
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1-Nitro-2-phenylethane is the ﬁrst nitro compound isolated
from plants [1]. It is a volatile compound found in the essential oil
of various species, and its presence provides a pleasant odor that
resembles the cinnamon scent [2]. The biogenesis of 1-nitro-2-
phenylethane derives from the ubiquitous amino acid precursor
phenylalanine through the production of phenylacetaldoxime via
cytochrome P450-dependent enzymes [2–5]. 1-Nitro-2-pheny-
lethane was also identiﬁed as a contributor to ﬂavor in tomatoes, in
which phenylalanine is ﬁrst decarboxylated by aromatic L-amino* Corresponding author. Departamento de Fisiologia e Farmacologia, Faculdade
de Medicina, Universidade Federal do Ceara´, R. Cel Nunes de Melo 1127 - Rodolfo
Teo´ﬁlo, Fortaleza, CE, Brasil, CEP 60430-270. Tel.: +55 85 3366 8334;
fax: +55 85 3366 8333.
E-mail address: pjcmagal@ufc.br (Pedro J.C. Magalha˜es).
0006-2952  2012 Elsevier Inc. 
http://dx.doi.org/10.1016/j.bcp.2012.12.012
Open access under the Elsevier OA license.acid decarboxylases to yield phenethylamine that may be
subsequently metabolized to 1-nitro-2-phenylethane [6].
Pharmacological information about 1-nitro-2-phenylethane
has only been provided recently. It induces biphasic hypotension
and bradycardia in either normotensive [7] or hypertensive [8]
rats, effects characterized by rapid (i.e., onset time of 1–3 s) and
slower (i.e., peak between 4 and 10 s) components that resemble
the cardiovascular response to capsaicin [9]. The ﬁrst rapid
bradycardic and hypotensive phase has a vago-vagal reﬂex origin
that results from the stimulation of vagal pulmonary rather than
cardiac C-ﬁber afferents and appears not to involve the activation
of either transient receptor potential vanilloid-1 or 5-hydroxy-
trypamine-3 receptors located on vagal sensory ﬁbers [7,8]. The
delayed second hypotensive phase results from a vasodilatory
effect, an action preliminarily conﬁrmed by the concentration-
dependent reduction of phenylephrine-induced contractions in
aortic [7] or mesenteric arterial [8] preparations. The mode by
which it induces such vasodilator effects is not yet known, and the
present study investigated the underlying mechanisms involved in
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rat aorta. The present results strongly argue for the involvement of
soluble guanylate cyclase (sGC) stimulation in the pharmacological
actions induced by this nitro compound.
2. Materials and Methods
2.1. Isolation of pure 1-nitro-2-phenylethane
1-Nitro-2-phenylethane was isolated in high-grade purity
(98%) from the essential oil of Aniba canelilla (H.B.K.) Mez. Its
wood bark was air-dried, crushed, and subjected to hydrodistilla-
tion (100 g, 4 h, 0.6% yield) in a Clevenger-type apparatus. The
specimen was collected in an area of the Cauaxi River, Municipality
of Paragominas, southeastern Para´ state, Brazil, in May 2005. The
plant identiﬁcation was conﬁrmed by taxonomists from the
herbarium of the Emı´lio Goeldi Museum, Bele´m, Para´ state, Brazil,
by comparing it with voucher no. MG174904. The analytical
conditions, oil composition, and retention indices of its constitu-
ents were previously reported [10–12]. The isolation of 1-nitro-2-
phenylethane was achieved by fractionating the oil (15 g) in a silica
gel chromatographic column using petroleum ether (isocratic
elution) and thin-layer chromatography (hexane-ethyl acetate,
9:1) to separate the purest fraction. The puriﬁed fraction was
analyzed in a gas chromatography/ﬂame ionization detector
(Thermo Focus) to determine its percentage content under the
following conditions: wall-coated open tubular DB-5ms fused
silica capillary column (30 m  0.25 mm; 0.25 mm ﬁlm thickness);
60–240 8C (3 8C/min) programmed temperature; 220 8C and
250 8C injector and detector temperatures, respectively; nitrogen
as carrier gas; splitless injection type (2 ml of a 1:1000 hexane
solution).
2.2. Animals
Male Wistar rats (200–280 g) were obtained from our
institutional vivarium (Department of Physiology and Pharmacol-
ogy, Federal University of Ceara, Fortaleza, Brazil) and handled in
accordance with the Guide for the Care and Use of Laboratory
Animals published by the United States National Institutes of
Health. Animal welfare and the experimental procedures were
approved by our Institutional Animal Ethics Committee (process
no. 47/09). The animals were housed in polypropylene cages in
groups of six with a 12 h/12 h light/dark cycle at room temperature
that ranged from 22 8C to 26 8C. Food and water were provided ad
libitum.
2.3. Solutions and drugs
Tissues were maintained in a physiological medium that
consisted of a modiﬁed Krebs-Henseleit solution (MKHS;
118.0 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.18 mM
MgSO47H2O, 2.5 mM CaCl2, 25.0 mM NaHCO3, and 11.0 mM
glucose). The salts were purchased from Merck (Darmstadt,
Germany) and Vetec (Rio de Janeiro, Brazil). In the experiments
using Ca2+-free conditions, CaCl2 was omitted from the normal
MKHS, and ethylene glycol-bis(b-aminoethyl ether)N,N,N0,N0-tetra-
acetic acid (EGTA; 0.1 or 1 mM) was added. 1-Nitro-2-phenylethane
was dissolved in 2% Tween 80 (v/v), brought to the indicated
concentration using MKHS, and sonicated immediately before use.
The highest vehicle concentration used in the bath chamber was
0.1% v/v being such a concentration devoid of signiﬁcant effects as
showed in previous studies [7,8,11]. Some of the experiments with
1-nitro-2-phenylethane were performed with vascular preparations
that were pre-incubated (10 min before applying a given contractile
stimulus) with several pharmacological tools at concentrations thatare recommended in the literature to investigate the involvement of
some metabolic pathways. To investigate the involvement of K+
channels, the following blockers were used: tetraethylammonium
for large-conductance Ca2+-activated K+ channels (BKCa), glyben-
clamide for K+ channels activated by adenosine triphosphate (ATP;
KATP), and 4-aminopyridine for voltage-operated K
+channels (Kv). To
induce sustained and equieffective contractions in isolated pre-
parations of small mesenteric arteries or aorta, the adrenergic
agonists norepinephrine (10 mM) and phenylephrine (1 mM) were
used, respectively. We also used 1,10-(2,4,6-trihydroxy-1,3-pheny-
lene)-bis-1-hexanone,2,4-(bis-1-ketohexyl)-phloroglucinol (Hyp9),
phorbol 12,13-dibutyrate, L-NG-nitroarginine methyl ester (L-
NAME), indomethacin, cis-N-(2-phenylcyclopentyl)-azacyclotri-
dec-1-en-2-amine hydrochloride (MDL-12330A), KT5720, methy-
lene blue, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ),
caffeine, and sodium nitroprusside. The rationale for using such
compounds is provided throughout the manuscript. All of the
reagents were purchased from Sigma (St. Louis, MO, USA).
2.4. Force measurement in isolated vessel bioassays
The animals were sacriﬁced by stunning and rapid exsangui-
nation. The thoracic aorta and second branch of the superior
mesenteric artery were obtained and cut as cylindrical ring-like
segments (1  5 mm and 0.2  2 mm, respectively). Contractions
were recorded with aortic rings disposed in a 5 ml organ bath. The
rings were attached by triangular steel wire pieces (0.3 mm
diameter) to isometric force transducers (ML870B60/C-V, AD
Instruments, Bella Vista, Australia) in a data acquisition system
(PowerLab 8/30, AD Instruments). The rings of the mesenteric
artery were disposed in a 610M-DMT Wire Myograph System
(DMT, Aarhus, Denmark) by two tungsten (40 mm) wires that
passed through the lumen of each ring, one ﬁxed to a micrometer
for length adjustments and the other connected to a force
transducer. The organ bath contained warm (37 8C) MKHS that
was continuously bubbled with 5% CO2 in O2. Aortic and
mesenteric arterial rings were stretched with a passive tension
of 1 g and 0.5 g, respectively. For endothelium denudation, the
intimal surface was gently rubbed with a stainless steel wire
(0.3 mm diameter), whereas tungsten wire (40 mm diameter) was
used to gently rub the luminal surface of the mesenteric artery
rings. The lack of endothelial functionality was conﬁrmed
pharmacologically by the absence of relaxation after the addition
of acetylcholine (1 mM) on the plateau of a phenylephrine
(0.1 mM)- or K+ (60 mM)-induced contraction in aortic or
mesenteric artery rings, respectively.
2.5. In silico docking analysis
The docking of 1-nitro-2-phenylethane in the sGC molecule was
performed using Autodock (version 4.0) [13] and a molecular
model (Ns H-NOX) of the subunit that contained the heme
fragment obtained in crystallographic studies (PDB identiﬁer
2O09_A) [14]. AutoDockTools software [15] was used to check the
molecular models by adding polar hydrogens (Kollman) and partial
charges (Gasteiger) to produce appropriate parameter ﬁles and
analyze the results. Atomic solvation parameters for the protein
and ﬂexible torsions for the ligand were assigned. Afﬁnity grid
ﬁelds were constructed with Autogrid by adopting the genetic
algorithm and local search combined option. The whole protein
was considered in an earlier step (blind docking) for the afﬁnity
grid calculations. The grid ﬁeld was inside a 46.6 A˚ side cube, with
grid points separated by 0.80 A˚. The number of energy evaluations
and docking runs were set to 250,000 and 50, respectively. All of
the other parameters were conserved as default. In a second step,
the grid ﬁeld was constructed with the center focused at ARG116
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with this residue in the ﬁrst step. The grid cube was maintained
with the same side size, number of energy evaluations, and
number of docking runs as the previous step, but the grid points
were separated by 0.37 A˚. In a third step, the grid side size was
reduced to 15 A˚, with grid points spaced by 0.37 A˚. The number of
energy evaluations was set to 25,000,000, and the number of
docking runs was set to 50. The protein structure was considered
rigid in all of the experiments. The 1-nitro-2-phenylethane
structure was made ﬂexible with three rotatable bonds.
2.6. cGMP assay
Cyclic guanosine 30,50-monophosphate (cGMP) was measured
with aortic rings disposed for 20 min in a 5 ml organ bath that
contained warmed (37 8C) MKHS that was bubbled with 5% CO2 in
O2. The tissues were exposed to either 1-nitro-2-phenylethane
(1984.6 mM; in the absence or presence of 10 mM ODQ or 30 nM
sodium nitroprusside for 1.5 min) and immediately frozen in liquid
nitrogen for storage at 80 8C until the analysis. The tissue
collected was homogenized and processed in 5% trichloroacetic
acid (TCA) and furthermore centrifuged at 1500  g for 10 min at
4 8C. The supernatant was transferred to a clean tube, and the
extraction of TCA from the sample was performed using water-
saturated ether. cGMP was measured by radioimmunoassay.
Tissues were weighed to standardize the different samples. The
preparation of tracers, samples, and standards and incubation with
antibody followed the instructions supplied by the manufacturer
(Cyclic GMP EIA kit; Cayman Chemical, Ann Arbor, MI, USA).
2.7. Statistical analysis
The data are expressed as mean  SEM, and n indicates the
number of experiments. The IC50 (i.e., the concentration of 1-nitro-2-
phenylethane at which 50% of a contractile response was inhibited)
values were calculated by interpolation from semi-logarithmic plotsFig. 1. (A) Chemical structure of 1-nitro-2-phenylethane and (B) its 1H nuclear magneti
CDCl3 as the solvent, furnishing signals of d = 7.27 (m, 5H, mono-substituted aromatic rin
a-position to aromatic ring). This spectrum matches the one that was previously reported
spectrum.and are reported as geometric means [95% conﬁdence interval].
Unpaired Student’s t-test and one- or two-way analysis of variance
(ANOVA) followed by the Holm–Sidak post hoc test were used to
compare differences between treatments. The IC50 values were
compared using the Mann–Whitney U-test. Statistical signiﬁcance
was accepted at p < 0.05. The data were analyzed using Systat
software (Chicago, IL, USA).
Fig. 1.
3. Results
3.1. Vasorelaxant effects of 1-nitro-2-phenylethane
In endothelium-intact or -denuded aortic rings, 1-nitro-2-
phenylethane (6.6–1984.6 mM) fully and concentration-depen-
dently relaxed (p < 0.001, ANOVA) the sustained contractions
induced by phenylephrine (1 mM; Fig. 2A), with IC50 values of
231.5 [154.1–348.0] mM (n = 22) and 172.0 [53.6–544.4] mM
(n = 7), respectively, values not statistically different (p > 0.05,
Mann–Whitney). 1-Nitro-2-phenylethane (0.7–1984.6 mM) also
relaxed the contractions induced by Hyp9 (100 mM) and phorbol
12,13-dibutyrate (1 mM), the latter maintained under Ca2+-free
conditions (MKHS that contained 1 mM EGTA; Fig. 2B, C), with IC50
values of 119.0 [74.8–191.2] mM (n = 7) and 203.1 [80.7–509.4]
mM (n = 7), respectively. In endothelium-intact mesenteric arterial
rings (Fig. 2A), 1-nitro-2-phenylethane (0.2–1984.6 mM) also
relaxed sustained contractions induced by norepinephrine
(10 mM), with an IC50 value of 43.0 [18.5–98.6] mM (n = 6), a
parameter not inﬂuenced by endothelium removal (IC50 of 29.1
[15.9–53.6] mM; n = 5; p > 0.05).
3.2. Involvement of intracellular cascades in the vasorelaxant effects
of 1-nitro-2-phenylethane
In aorta, the relaxant effects of 1-nitro-2-phenylethane on
phenylephrine-induced contractions were not changed byc resonance (NMR) spectrum obtained in a Varian Mercury NMR at 300 MHz using
g), d = 4.61 (t, 2H, J = 7.5 Hz, a-position to nitro group), and d = 3.33 (t, 2H, J = 7.5 Hz,
 [12]. The insets in B present a more extended view of the peaks shown in the entire
Fig. 2. Vasorelaxant effects of 1-nitro-2-phenylethane. (A) Concentration-effect curves for the relaxant effects of 1-nitro-2-phenylethane (NPE) in endothelium-intact (E+)
and -denuded (E) aortic (6.6 to 1984.6 mM; E+ n = 22; E n = 7) and mesenteric arterial (0.2 to 1984.6 mM; E+ n = 6; E n = 5) rings. Sustained contractions were induced by
phenylephrine (1 mM) in aorta and by norepinephrine (10 mM) in mesenteric arterial rings and are expressed as a percentage of the contraction immediately before the
addition of NPE. (B) Typical trace recordings and (C) graphical representation of NPE (0.7 to 1984.6 mM)-induced inhibition of contractions induced by Hyp9 (100 mM; n = 7)
and phorbol 12,13-dibutyrate (PDBu, 1 mM; n = 7), the latter under Ca2+-free conditions. The data are expressed as mean and SEM. Calibrations: vertical 0.5 g, horizontal
10 min. *p < 0.05, compared with respective control (Ctrl; one-way ANOVA followed by Holm–Sidak test).
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mM; n = 6), indomethacin (10 mM; IC50 of 299.7 [136.3–658.9]
mM; n = 6), MDL-12330A (3 mM; IC50 of 219.0 [109.8–438.6] mM;
n = 7), or KT 5720 (1 mM; IC50 of 275.2 [205.1–369.1] mM; n = 8;
Fig. 3A). In contrast, the IC50 values were signiﬁcantly (p < 0.05,
Mann–Whitney) higher when the preparations were pretreated
with tetraethylammonium (TEA; 5 mM; IC50 of 644.3 [478.3–
867.3] mM; n = 7), glybenclamide (10 mM; IC50 of 484.9 [421.4–
557.0] mM; n = 10), 4-aminopyridine (4-AP; 1 mM; IC50 of 591.4
[344.0–1016.8] mM; n = 5; Fig. 3B), and methylene blue (10 mM;
IC50 of 705.9 [498.8–998.3] mM; n = 9; Fig. 3 C). The relaxing effects
of 1-nitro-2-phenylethane were also signiﬁcantly (p < 0.05,
ANOVA) reduced by ODQ (Fig. 3 C), with an IC50 value that
although not calculated could be estimated to be higher than
2000 mM (n = 6).3.3. Inﬂuence of the guanylate cyclase heme oxidant ODQ on the
inhibitory effects of 1-nitro-2-phenylethane on contractile responses
mediated by intracellular pathways: comparison with sodium
nitroprusside
In a separate set of aortic rings under Ca2+-free conditions
(MKHS without CaCl2 that contained 0.1 mM EGTA), a transient
(phasic) contraction was initially observed when the preparations
were exposed to norepinephrine (1 mM; Fig. 4A and B). Such a
procedure was repeated while maintaining the tissue in the virtual
absence of Ca2+. After four successive stimuli, the phasic
contraction almost entirely disappeared, suggesting that the
internal exhaustion of Ca2+ stores was reached. After norepineph-
rine removal by repeated washes (4) with the Ca2+-free solution,
external Ca2+ levels increased to 2 mM, causing a sustained
Fig. 3. Pharmacological investigation of the role of intracellular cascades that
underlie the vasorelaxant effects of 1-nitro-2-phenylethane. (A) Graph that shows
that L-NAME (100 mM; n = 6), indomethacin (INDO, 10 mM; n = 6), KT 5720 (1 mM;
n = 8), and MDL 12,330 A (3 mM; n = 7) did not interfere with the relaxant effect
induced by 1-nitro-2-phenylethane (NPE; 6.6 to 1984.6 mM) in endothelium-intact
aorta contracted with phenylephrine (1 mM). Conversely, a signiﬁcant shift to the
right was observed after pretreatment with the (B) potassium channel blockers
tetraethylammonium (TEA; 5 mM; n = 7), glybenclamide (GLIB; 10 mM; n = 10),
and 4-aminopyridine (4-AP; 1 mM; n = 5) and (C) guanylate cyclase inhibitors
methylene blue (MB; 10 mM; n = 9) and ODQ (10 mM; n = 6). The data are expressed
as mean and SEM. *p < 0.05, compared with control curve (two-way ANOVA).
Fig. 4. Inﬂuence of guanylate cyclase oxidation on the inhibitory effects of 1-nitro-
2-phenylethane on contractile responses mediated by intracellular pathways and
comparison with sodium nitroprusside. (A) Trace recordings and (B) graphical
representation that show that repeated stimulation (1 to 4) of aortic rings with
norepinephrine (NE; 1 mM) while maintaining the tissue under Ca2+-free conditions
produced a gradual decrease in NE-induced phasic contractions that are typical of
internal Ca2+ store depletion. The black bar indicates a reference NE-induced
contraction in Ca2+-containing medium. Agonist removal by washing with Ca2+-free
MKHS (*) and subsequent Ca2+ (2 mM) restoration (!) in the extracellular
medium still in the absence of NE produced a sustained contraction that was
inhibited by 1-nitro-2-phenylethane (NPE; n = 7), an effect not observed in the
presence of ODQ (n = 7). (C) The ﬁrst phasic contraction induced by phenylephrine
(PHE) in Ca2+-free medium (represented as Ctrl) was also inhibited by 1-nitro-2-
phenylethane (n = 6) and sodium nitroprusside (SNP; n = 6). Both effects were
prevented by ODQ. In contrast, contractions induced by caffeine in a Ca2+-free
medium (Ctrl in D) were not signiﬁcantly changed. In C and D, black bars indicate a
reference 60 mM K+-induced contraction in Ca2+-containing medium. The data are
expressed as mean and SEM. In B, *p < 0.05, compared with response 1 (one-way
ANOVA followed by Holm–Sidak test). In B and C, #p < 0.05, compared with control
(Ctrl) group in each panel (ANOVA followed by Holm–Sidak test).
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tion induced by norepinephrine (1 mM) in Ca2+-containing medium. In
the presence of 661.5 mM 1-nitro-2-phenylethane, this Ca2+-induced
sustained contraction was almost entirely inhibited and corresponded
toonly 0.9  0.1% of the reference contraction (p < 0.05, Student’s t-test;
Fig. 4B). Conversely, when the aortic rings under Ca2+-free conditions
were pretreated with ODQ (10 mM) before Ca2+ restoration, 1-nitro-2-
phenylethane did not exert any inhibitory effect, and the sustained Ca2+-
induced contractions corresponded to 43.8  6.9% (n = 7), values that
were not signiﬁcantly different from the same response in the absence of
1-nitro-2-phenylethane and ODQ (p > 0.05; Fig. 4B).
In a separate set of experiments, aortic rings maintained under
Ca2+-free conditions (MKHS without CaCl2 that contained 1 mMEGTA) were stimulated with either phenylephrine (1 mM; Fig. 4C)
or caffeine (10 mM; at 25 8C to induce contractions under Ca2+-free
conditions [16]; Fig. 4D). Both treatments induced transient
contractions that corresponded to 41.4  1.1% (n = 10) and
35.9  3.2% (n = 12), respectively, of a reference contraction induced
by 60 mM K+. The transient contraction induced by caffeine was not
changed by 1-nitro-2-phenylethane or sodium nitroprusside, but the
contractions induced by phenylephrine were signiﬁcantly (p < 0.05,
unpaired Student’s t-test) reduced to 18.2  1.2% and 12.2  1.8% by
1-nitro-2-phenylethane (661.5 mM) and sodium nitroprusside
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nitroprusside-induced reductions were not observed in preparations
that were previously treated with ODQ.
3.4. In silico analysis of the molecular interaction between 1-nitro-2-
phenylethane and guanylate cyclase
The computational docking analysis suggested that 1-nitro-2-
phenylethane docked major conformations that were distributed
into one main site near the heme group, which was observed as a
pocket on the macromolecule surface (Fig. 5A and B). After the
third docking step, the best conformations were consistently
concentrated at this main site in a series of 50 docking runs,
whereas building the grid ﬁeld using the most restricted mesh led
to more uniformity in the docked molecules. The lowest binding
energy was 4.64 kcal/mol, with the closest atom in 1-nitro-2-
phenylethane 1.9 A˚ away from ARG116 (Fig. 5C). The ligand was
also located 2.7 A˚ from the amino acid MET1 in the proximal
extremity of the a-A helix (Fig. 5D). The predicted binding site was
also close to the proximal extremity of the a-C helix but
maintained a certain distance from the coil following the a-F
helix. Beyond ARG 116 and MET1, the residues of the heme group,
consisting of TYR2, ALA42, TYR43, SER44, ASP45, GLN114, LEU115,
and ARG138, were the closest residues selected within 5 A˚ from theFig. 5. In silico analysis of the molecular interaction between 1-nitro-2-phenylethane and
2-phenylethane (NPE; highlighted in blue) and the soluble guanylate cyclase subunit th
main site were observed as a pocket on the macromolecule surface. (C, D) The closest atom
acid MET1. (E) The closest residues selected within 5 A˚ of the docked NPE molecule. (F) T
nitro group followed an orientation directed to ARG116.docked molecule of 1-nitro-2-phenylethane (Fig. 5E). The ring
portion of 1-nitro-2-phenylethane was oriented to hydrophobic
residues, whereas the nitro group followed an orientation that was
directed to ARG116 in the pocket border (Fig. 5F).
3.5. Effect of 1-nitro-2-phenylethane on cGMP levels in aortic tissues
The basal levels of cGMP in homogenates of endothelium-intact
aortic rings corresponded to 2.1  0.2 pmol cGMP/mg of tissue
(n = 4; Fig. 6). In rings treated with 1-nitro-2-phenylethane
(1984.6 mM), cGMP levels signiﬁcantly (p < 0.05, Student’s t-test)
and markedly increased above control values to 5.3  0.9 pmol
cGMP/mg of tissue. Treatment with ODQ (10 mM) reduced the 1-
nitro-2-phenylethane-induced increase in cGMP levels to a level that
was equivalent to the level observed under basal conditions
(2.2  0.2 pmol cGMP/mg of tissue). In rings treated with the NO
donor sodium nitroprusside (30 nM), cGMP levels also markedly
increased above control values (6.4  1.0 pmol cGMP/mg of tissue;
n = 4).
4. Discussion
The present study showed that a compound with rare natural
occurrence, 1-nitro-2-phenylethane, has relaxant properties in rat guanylate cyclase. (A) Molecular model of the putative interaction between 1-nitro-
at contained the heme fragment (in red). (B) Major conformations docked into one
 in the NPE molecule was 1.9 A˚ away from ARG116 and 2.7 A˚ away from the amino
he ring portion of NPE was oriented to hydrophobic residues (yellow), whereas the
Fig. 6. Effect of 1-nitro-2-phenylethane on cGMP levels in aortic tissues. The graph
shows the increase in cGMP levels induced by 1-nitro-2-phenylethane (NPE;
1984.6 mM; n = 4) in rat aortic rings. Such an effect was comparable to the effect
induced by sodium nitroprusside (SNP; 30 nM; n = 4) and was blunted by treatment
with ODQ (10 mM; n = 4). The data are expressed as mean and SEM. a,bp < 0.05,
compared with values of control and NPE groups, respectively (ANOVA followed by
Holm–Sidak test).
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In silico simulation with a heme nitric oxide (H-NOX) domain
homolog predicted the existence of a pharmacophore alignment
between 1-nitro-2-phenylethane and sGC. The vasodilator actions
of 1-nitro-2-phenylethane appeared to derive from its ability to
augment cGMP levels in smooth muscle cells, ﬁndings that
strongly argue for the involvement of sGC stimulation in such
vasodilator effects.
The vasorelaxant actions were concentration-dependent in
tissues upon equieffective contractile stimulation induced by the
adrenergic compounds phenylephrine and norepinephrine. Inter-
estingly, 1-nitro-2-phenylethane more potently relaxed mesen-
teric arterial than aortic rings, a ﬁnding that corroborates its
previously reported potent hypotensive effect on diastolic arterial
blood pressure [7,8]. Although we are unable to presently explain
the higher potency of 1-nitro-2-phenylethane in mesenteric
arterial vessels, such a feature suggests a preferential action of
this compound in tissues that are more involved in hemodynamic
control and ultimately determine peripheral vascular resistance
[17]. The effects induced by 1-nitro-2-phenylethane appeared to
result from its intracellular actions because they occurred within a
narrow potency range against other contractile agents that do not
activate adrenergic receptors, such as the phorbol ester 12,13-
dibutyrate and the hyperforin analog Hyp9, thus precluding the
occurrence of competitive antagonism on membrane receptors.
Indeed, phorbol 12,13-dibutyrate-induced contractions under
Ca2+-free conditions occur through protein kinase C activation
[18], whereas Hyp9 activates Ca2+ inﬂux through the canonical
transient receptor potential-6 (TRPC6) [19].
The involvement of prostaglandins on the effects induced by 1-
nitro-2-phenylethane is similarly unlikely because vasorelaxation
was not changed by indomethacin [20]. The inhibition of adenylyl
cyclase with MDL-12330A [21] or cAMP-dependent protein kinase
A with KT-5720 [22] also did not interfere with its relaxant actions.
Similarly, neither endothelium removal nor L-NAME-induced
nitric oxide (NO) synthase inhibition inﬂuenced vasodilation in
aortic rings, suggesting that the endothelial release of NO is not
involved. Considering that the experiments that used antagonists
were performed in preparations that were separate from those
with 1-nitro-2-phenylethane alone and that only some concen-
tration-effect curves were signiﬁcantly shifted to the right, theputative occurrence of tolerance can be discarded. Indeed,
experiments in endothelium-intact aortic rings under repeated
(i.e., ﬁve repetitions separated by 15 min intervals) exposure to 1-
nitro-2-phenylethane (200 mM) resulted in relaxant responses of a
similar order of magnitude (data not shown). In vivo studies in
either normotensive [7] or hypertensive [8] rats also indicate that
the occurrence of tolerance in the cardiovascular effects of 1-nitro-
2-phenylethane is unlikely.
In addition to vascular relaxation, 1-nitro-2-phenylethane also
increased cGMP levels in aortic rings. Notably, these effects were
signiﬁcantly inhibited by the guanylate cyclase inhibitor ODQ [23].
Methylene blue, another guanylate cyclase inhibitor [24], also
reduced the vasodilator effect of 1-nitro-2-phenylethane in aortic
rings. Corroborating the effects of Hyp9, 1-nitro-2-phenylethane
decreased the transient contraction induced by capacitative Ca2+
entry triggered by Ca2+ store depletion following repeated
stimulation with norepinephrine and subsequent Ca2+ restoration
[25], an effect blocked by ODQ. Similarly, the supposedly inositol
triphosphate-induced transient contraction caused by stimulation
with phenylephrine under Ca2+-free conditions [26] was inhibited
by 1-nitro-2-phenylethane in an ODQ-preventable manner. Some
of these effects of 1-nitro-2-phenylethane resembled the effects
induced by sodium nitroprusside, in which this NO donor was able
to decrease the transient contraction induced by phenylephrine in
a Ca2+-free medium in an ODQ-preventable manner. Similar to 1-
nitro-2-phenylethane, sodium nitroprusside increased cGMP
levels in aortic tissues. Conversely, the phasic contractile response
induced by caffeine under Ca2+-free conditions, which results in
activation of a Ca2+-induced Ca2+ release mechanism mediated by
the ryanodine receptor-elicited opening of Ca2+ channels in the
sarcoplasmic reticulum [27], was the only contractile response not
presently inﬂuenced by 1-nitro-2-phenylethane. Other authors
reported similar ineffectiveness of sodium nitroprusside against
caffeine-induced contractions under Ca2+-free conditions [28–30].
Therefore, the present ﬁndings suggest that the vasorelaxant
effects of 1-nitro-2-phenylethane involve stimulation of the sGC
pathway.
One might consider the possibility that 1-nitro-2-phenylethane
is a NO donor. The spontaneous release of NO from 1-nitro-2-
phenylethane, however, is unlikely because the –NO2 group is
disposed in a small aliphatic chain attached to an aromatic ring with
resonance properties that are able to delocalize electrons of the
symmetric p-orbital system in the aromatic ring to satisfy the
nitrogen’s positive charge imposed by the electronegative inﬂuence
of oxygen atoms (Fig. 1) [31]. Additionally, its chemical structure
differs from classical NO donors that generally possess nitrate or S-
nitroso groups, which are the source for NO [32]. In vascular smooth
muscle cells, the guanylate cyclase’s heme moiety is the major
endogenous intracellular site that binds NO, augmenting the
catalytic activity of the enzyme several hundred-fold and resulting
in cGMP from guanosine triphosphate. Notwithstanding, 1-nitro-2-
phenylethane unlikely displaces the original histidine (HIS105) by
directly binding to the ﬁve-coordinate ferrous heme (Fe[II]), which
occurs with NO [33]. Although not presently addressed, a putative
hypothesis is that P450 (CYP)-catalyzed conversion is able to release
NO from 1-nitro-2-phenylethane, which has already been shown for
glyceryl trinitrate [34].
Interestingly, myorelaxation and the stimulation of cGMP
production are properties also reported for sGC stimulators, such
as YC-1 and BAY 41–2272 (i.e., indazole compounds that were
discovered in the 1990s) [35]. They relax aortic ring contractions
induced by phenylephrine, and their effects are signiﬁcantly
inhibited by ODQ. In contrast, the vasodilator actions of YC-1 and
BAY 41–2272 clearly depend on the endothelial release of NO [36–
38]. The lead compound, YC-1, also inhibits phosphodiesterase V,
an action that may further induce an increase in cGMP levels [39].
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phosphodiesterase function is unlikely because the vasodilator
effects of most phosphodiesterase inhibitors are reduced as much
by endothelium removal as by L-NAME treatment [40,41], which
strongly differed from the present ﬁndings for 1-nitro-2-pheny-
lethane. Moreover, the median effective concentrations of 1-nitro-
2-phenylethane were quite high. Notably, however, the IC50 values
of 43 and 29 mM observed in the present study in endothelium-
intact and -denuded mesenteric arterial vessels, respectively, are
comparable to the potency range for smooth muscle relaxation of
sGC stimulators. For example, BAY 41–2272 relaxes the rat basilar
artery with an IC50 of 0.1 mM, whereas A-350619 relaxes the
corpus cavernosum with an IC50 of 80 mM [35].
The hypothesis that 1-nitro-2-phenylethane may exert direct
sGC stimulation was addressed in the present study using in silico
simulation of the molecular interaction between 1-nitro-2-
phenylethane and (Ns) H-NOX, a heme protein obtained from
symbiotic cyanobacteria Nostoc sp., which possesses high struc-
tural homology (approximately 35% sequence identity to the b-
subunit found in mammalian sGC) and similar apparent in vivo
function [42]. Such an approach revealed the existence of a main
site that is able to dock 1-nitro-2-phenylethane based on at least
50 best conformations that were all consistently concentrated in a
pocket of the macromolecule surface and displayed a main spatial
orientation inside the pocket with the ring portion facing
hydrophobic residues within the cavity. The portion with oxygen
content bent to the external border, reclining within the proximity
of the amino acid ARG116.
Residues situated at a maximal distance of 5 A˚ between the
predicted binding site and docked molecule of 1-nitro-2-pheny-
lethane were identiﬁed [43]. Because these residues were
distributed into one main site in proximity to the heme group,
perhaps 1-nitro-2-phenylethane could mediate crosstalk between
non-heme groups that induce NO-independent but heme-depen-
dent allosteric improvement of the guanylate cyclase’s catalytic
unity. Indeed, conventional guanylate cyclase stimulators, such as
YC-1 and BAY 41–2272, appear to have a common allosteric site
that targets their stimulatory actions on this enzyme [43–45].
Heme-dependency is characterized by the decreased stimulatory
inﬂuence of sGC stimulators after heme removal or oxidation by
ODQ, methylene blue, or ferri-cyanide [35]. Conversely, heme
removal or oxidation does not interfere with the effects of BAY 58–
2667, which may produce guanylate cyclase stimulation in a NO-
and heme-independent manner. Substances that are able to
increase cGMP levels by heme-independent stimulation of sGC
prompted the formation of a novel class called ‘‘sGC activators’’
[35]. Altogether, if a direct stimulatory action on sGC can be
conﬁrmed using more appropriate methods, then 1-nitro-2-
phenylethane may likely be characterized as a sGC stimulator
rather than activator.
Additional events may also contribute to the relaxant effects of
1-nitro-2-phenylethane, such as the opening of K+ channels in
plasmalemma, a phenomenon apparently conﬁrmed using K+
channel blockers, which signiﬁcantly shifted the concentration-
effect curve to the right in response to this nitro compound. Such
ﬁndings are consistent with the hypothesis that 1-nitro-2-
phenylethane stimulates the sGC pathway. Generally, sGC-derived
cGMP will target three main cellular sites: cGMP-dependent
protein kinases (PKGs), cGMP-gated cation channels, and phos-
phodiesterases [46]. Speciﬁcally, the opening of K+ channels is one
of the possible events that result from cGMP accumulation in the
cytoplasm, promoting subsequent vasodilation [47]. However, the
present ﬁndings do not discard the putative hypothesis of a direct
opening effect of 1-nitro-2-phenylethane on K+ channels.
In conclusion, 1-nitro-2-phenylethane appeared to exert
vasodilator effects that were compatible with the expected proﬁleof a substance that induces sGC stimulation and improves cGMP
production in aortic tissues. Such sGC stimulation does not depend
of endothelial NO release but appears to depend on a functional
heme group.
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